Skip to content

Visual Outcomes After Vivity Toric IOL Implantation

Patient Satisfaction and Visual Outcomes After Bilateral Implantation of a Novel Non-Diffractive Extended Vision Toric Intraocular Lens

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04675489
Enrollment
4
Registered
2020-12-19
Start date
2021-01-15
Completion date
2021-12-13
Last updated
2022-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractive Assessment

Keywords

Vivity, Extended Vision Toric Intraocular Lens, Patient satisfaction and visual outcomes

Brief summary

The purpose of this study is to evaluate patient satisfaction after bilateral implantation of Vivity Toric Extended Vision Intraocular lens and visual outcomes.

Detailed description

To evaluate and report outcomes including postoperative uncorrected visual acuity, postoperative best corrected visual acuity, postoperative refractive error, and IOL rotational stability after Vivity Toric Extended Vision intraocular lens (IOL) implantation.

Interventions

OTHERProcedure: Vivity Toric IOL

The U.S. Food and Drug Administration (FDA) has granted approval of Alcon's Vivity Toric Extended Vision intraocular lens (IOL) for cataract patients. This innovative lens is an extended depth of focus IOL that has been reported to result in fewer visual disturbances than diffractive IOLs.

Sponsors

Alcon Research
CollaboratorINDUSTRY
Icon Eye Care
CollaboratorOTHER
EVP Eye Care
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

Subjects to receive bilateral implantation of Vivity Extended Vision Toric Intraocular Lens

Eligibility

Sex/Gender
ALL
Age
45 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Calculated lens power within study IOL range of 15.0 diopters to 25.0 diopters and toric range of T3 to T6 * Willing and able to comprehend informed consent form and to complete 1 day and 3-4 month postoperative visit * Potential postoperative best corrected distance visual acuity of 20/20 or better in each eye based on medical opinion of investigator

Exclusion criteria

* Ocular pathology or comorbidity that could reduce potential postoperative best corrected distance visual acuity * Ocular trauma or zonular weakness/instability * Diagnosis of glaucoma or high-risk glaucoma suspect * Previous refractive surgery * Unreliable preoperative biometry measurements * Severe dry eye or ocular surface disease

Design outcomes

Primary

MeasureTime frameDescription
Binocular best distance-corrected near visual acuity4 monthsBinocular best distance-corrected near visual acuity
Monocular visual acuity at distance4 monthsMonocular uncorrected distance visual acuity
Binocular visual acuity at distance4 monthsBinocular uncorrected distance visual acuity
Monocular best corrected distance visual acuity4 monthsMonocular best corrected distance visual acuity
Binocular best corrected distance visual acuity4 monthsBinocular best corrected distance visual acuity
Monocular best distance-corrected intermediate visual acuity4 monthsMonocular best distance-corrected intermediate visual acuity
Binocular best distance-corrected intermediate visual acuity4 monthsBinocular best distance-corrected intermediate visual acuity
Monocular best distance-corrected near visual acuity4 monthsMonocular best distance-corrected near visual acuity

Secondary

MeasureTime frameDescription
Residual refractive cylinder4 monthsManifest postoperative refractive cylinder (measured in diopters, with a phoropter) after cataract surgery and IOL implantation.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026